A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

Inclusion Criteria: * Participants who are overtly healthy as determined by medical history and physical examination. * Have body mass index (BMI) equal to or greater than 27 kilograms per meter squared (kg/m²), inclusive, at screening. * Have an estimated glomerular filtration rate equal to or greater than 60 milliliters per minute (mL/min). * Males and females who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP). * Have venous access sufficient to allow for blood sampling. Exclusion Criteria: * Have any type of diabetes with hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater. * Have significant history of or currently have Major Depressive Disorder or psychiatric disorder within the last 2 years. * Obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome. * Have known clinically significant gastric emptying abnormality. * Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass) * Have a known self or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroid cancer. * Have an abnormal 12-lead electrocardiogram (ECG) at screening. * Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drug. * Participants must not be currently participating in or completed a clinical trial within the last 90 days.…